The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Solid Biosciences Inc. is preparing for a sit-down with the U.S. FDA this year to discuss the firm’s results with the next-generation gene therapy SGT-003 for Duchenne muscular dystrophy (DMD).

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Schwartz believes that the DMD program is just the beginning for Solid Biosciences, with the potential for their cardiac pipeline to drive the company's growth beyond DMD. The INSPIRE DUCHENNE trial ...

Solid Biosciences’ gene therapy candidate for patients with Duchenne muscular dystrophy (DMD) has elicited a 110% expression of the microdystrophin gene. The US-based company’s stock soared by ...

Duchenne Muscular Dystrophy (DMD) is caused by a lack of functional ... they could raise their expectations significantly. Solid Biosciences' recent results are highly encouraging for its future.